Another Heavy Metal Under Fire
The FDA updated a public health advisory today about a serious new kidney disease that is apparently associated with a gadolinium-based contrast agent used with MRI or MR angiography.
— As of Dec. 21, 2006 there have been reports of 90 patients with moderate to end-stage kidney disease who developed a new disease, called nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD), after they had an MRI or MRA with a gadolinium-based contrast agent. — The signs of NSF/NFD also include: burning, itching, swelling, hardening and tightening of the skin; red or dark patches on the skin; yellow spots on the whites of the eyes; stiffness in joints with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness.

Click to See Report Before and After Treatment  Gadolinium

The agency said that as of Dec. 21, 2006 it had received reports of 90 patients with moderate to end-stage kidney disease who developed the new disease, called nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD), after they had an MRI or MRA with a gadolinium-based contrast agent.

The FDA recommended that whenever possible patients with moderate to end-stage kidney disease who need an imaging study, be given imaging methods other than MRI or MRA with a gadolinium-based contrast agent.

NSF/NFD began from two days to 18 months after exposure to the contrast agent, said the FDA. Many, but not all of these patients, received a high dose of the contrast agent, yet some received only one dose.

The signs of NSF/NFD also include: burning, itching, swelling, hardening and tightening of the skin; red or dark patches on the skin; yellow spots on the whites of the eyes; stiffness in joints with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness.

The FDA notified physicians and patients that:

• Patients with moderate to end-stage kidney disease who receive an MRI or MRA with a gadolinium-based contrast agent may get NSF/NFD which is debilitating and may cause death.
• Patients who believe they may have NSF/NFD should get in touch with their doctor. Patients who develop NSF/NFD have areas of tight, rigid skin and may have scarring of their body organs.
• If these patients must receive a gadolinium-based contrast agent, prompt dialysis following the MRI or MRA should be considered.
• It is not clear why NSF/NFD occurs in patients with moderate to end-stage kidney disease who receive a gadolinium-based contrast agent.

There are five FDA-approved gadolinium-based contrast agents, Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance. These contrast agents are FDA approved for use during an MRI scan, but not for use during an MRA scan. Although NSF/NFD has been reported for only three of the five gadolinium-based contrast agents, the FDA said it believes that there is a potential for NSF/NFD to occur with the use of any of the approved gadolinium-based contrast agents.

The advisory was an update to an alert last June when the FDA said it had learned of 25 cases of NSF/NFD in patients with kidney failure who received Omniscan, and took the MRA test. "These reports provide more evidence for a causal relationship between gadolinium-based contrast agents and the development of NSF/NFD," the FDA said.

Worldwide, there have been about 215 patients with NSF/NFD reported, said the FDA. The medical histories of 75 of these patients were reviewed in detail, and all of the patients had received a gadolinium-based contrast agent for an MRI or MRA. Researchers, the agency said, have identified gadolinium in skin biopsies of patients with NSF/NFD.

Dr. Farr's Comment

I personally have seen gadolinium show up in my patient's toxic urine profiles and the link above with the report confirms this. The effects of this agent are very clearly defined in the FDA report, but, as with any FDA report, the findings only show that this agent presents problems in people who already have chronic kidney disease.

You have to ask yourself if it makes any sense at all to inject a person with a radioactive substance and if there won't be repercussions even if not measured in death. Common sense dictates that ANY radioactive metal put in the body is eventually going to cause some type of problem.

Take a Free Test

Take this preliminary to see if your condition could respond to treatment.

Not sure on your treatment options? For a limited time you can schedule a to talk with a licensed doctor or clinician regarding your condition.

Use our to find a doctor in your area.